NeoTherapeutics Inc.:

The Irvine company, which researches and develops treatments for neurological diseases, posted a first-quarter net loss of $9.3 million, or $1.02 a share, compared with a net loss of $4.4 million, or 71 cents a share, a year ago. No revenue was reported.